Highlights

1. Ready-to-scale biotech innovator with traction, targeting an $8.46B US market
2. Preclinically tested, innovative compound. Backed by 40+ studies, US-based production & distribution
3. 2M+ units sold globally, 54 patents globally, 3 US patents
4. SAFE round $250K–$300K: early investors convert at a discount next round, up to 3.57× (+257%) upside

Problem

• Over 260 million (76%) Americans are affected by mental health challenges.
• Most frequent conditions: stress, ADHD, depression, anxiety, burnout, mood swings, insomnia, inability to focus, brain fog.

Today’s solutions arrive too late

Most treatments focus on managing symptoms that have developed over the years.
America needs a new kind of intervention — the one that breaks the cycle of stress.

• That supports the brain before it reaches a breaking point.
• That changes how cognitive and emotional challenges begin, spread, and escalate.

Our Solution

Every psychiatrist knows: lithium works.

Lithium carbonate, the most commonly used form of lithium, since 1949, is notorious for its high toxicity and associated side effects.

By reengineering this gold-standard molecule, we created a 21st-century mental health solution.

Our scientific team has discovered that lithium and vitamin C form a compound with extraordinary brain benefits, without unwanted side effects.

Through research and preclinical validation, we transformed this discovery into Normotim, a patented formula (3 US Patents 10849878-B2, 10456373-B2, 11219641-B2) helping to reclaim mental clarity and emotional balance.

Backed by Years of Research

We’ve conducted 40+ studies and published 20+ peer-reviewed papers.

Full preclinical program - successfully completed.

How It Works?

Chronic stress impacts everything: mood, sleep, memory, decision-making, self-esteem.

The worse you feel, the harder it is to think clearly. Anxiety rises. Energy drops. Sleep suffers.

Stress feeds on that, forming a self-reinforcing loop that drags mental health down.

Lithium Ascorbate disrupts the stress cycle.

Preclinical studies show it blocks stress hormones, helping the brain stay calm and clear.

When stress is removed, everything else improves:

• Lithium ascorbate blocks stress hormones, helping reduce the levels of depression by 39% and anxiety by 35% on the Hospital Anxiety and Depression Scale (HADS) in 60 days.
• Increases brain-derived neurotrophic factor (BDNF) by 9%. BDNF is a neurotrophic agent crucial for thinking, memory, neuroplasticity, and neuronal survival. It promotes connections between neurons, boosting memory, ability to learn, and cognitive function.
• Improves memory by lowering levels of anxiety, depression, and chronic stress — visual memory by 83%, auditory-verbal memory by 98%, and muscle memory by 83%.
• Helps protect the brain from glutamate-induced stress after stroke, doubling neuron survival.
• Under prolonged alcohol toxicity, it doubles neuron survival (18% vs 36%).

Why Now?

• The mental & brain health supplement market is growing fast.The Global Mental Well-Being Supplements Market was valued at $11.48 billion in 2025 and is projected to grow at a CAGR* of 8.62% to reach a market value of $17.36 billion by 2030 [source].
• The US Mental Well-Being Supplements Market accounts for approximately 40% of the global market, estimated at $4.83 billion in 2025, and expected to reach $7.30 billion by 2030.
• The US brain health supplements market was estimated at $3.63 billion in 2025 and is expected to reach $6.90 billion by 2032, with a CAGR of 9.6% [source].

We conservatively target to capture 0.8% of the US mental & brain health supplement market by 2030 — $130M.

Lithium Is Trending in Science and Media

Over the past two months, two of the world’s most prestigious scientific journals have published landmark research on lithium’s role in brain health.

• On August 6, 2025, Nature released "Brain lithium deficiency in Alzheimer’s disease and reversal of pathology and memory deficits by lithium orotate in mouse models", showing that lithium deficiency in the brain may underlie Alzheimer’s disease, and that lithium compounds can reverse memory loss in mice.
• On June 9, 2025, The Lancet Psychiatry published "Lithium as a disease-modifying drug for bipolar disorder", reviewing its unique long-term neuroprotective potential.
• On August 9, 2025 The Washington Post have called this research a potential “game-changer” for brain health.

Our Current Stage

In the first stage, we built everything needed to scale: marketing and sales infrastructure.

What we've accomplished to date:

• Completed the full R&D phase and preclinical research program.
• Launched two products — Normotim and Lithium Ascorbate 1 mg.
• Built strong marketing channels, social media, Meta Ads, Google Ads, SEO, and PR.
• Launched an affiliate program that now includes 1,336 influencers who regulary post and stream their reviews of our products across Instagram, TikTok, Amazon Storefront, and Amazon Live.
• Established multiple sales channels: Amazon, TikTok Shop, and our own webstore Normotim.com.

Next Stage

• 2 additional products in the Lithium Ascorbate line are launching in 2026.
• Formulations for 4 tailored supplements are currently in development, with a planned launch in 2026.

• Antiage → Cognitive Aging & Burnout
• Alcostop → Addiction & Impulse Control
• Neuro → Chronic Stress & Emotional Dysregulation

Weight Loss → Emotional Eating & Metabolic Dysregulation

By the end of 2026 we will have 2 product lines and 8 supplements in total.

• Funds raised in the SAFE round will be dedicated to launching new products and scaling online advertising and sales.

How This SAFE Round Works

This round is structured as a SAFE (Simple Agreement for Future Equity).

That means you’re not buying shares today but your investment converts into equity at the next priced financing round.

• The company is raising $250K–$300K in this SAFE round.
• The valuation cap is $7M. This is the maximum valuation at which your investment can convert into shares.
• If the company grows and raises its next round at a higher valuation ($10M–$25M), your SAFE converts as if you invested earlier at a lower price per share.

In the illustrated scenarios, each $1 invested may convert into approximately $1.43–$3.57 in equity, depending on the company’s valuation at conversion.

Additionally, the SAFE includes an early-investor discount, meaning your investment converts into equity at a reduced price per share compared to new investors in the next round, rewarding you for investing early.

This means your SAFE investment will convert based on the company’s valuation at the next priced round, with potential growth equivalent to the illustrated percentage upside.

• 1.43× → +43% potential upside
• 2.14× → +114% potential upside
• 3.57× → +257% potential upside

We reimagined lithium — now we’re scaling to bring it to millions.

Become part of the next mental health breakthrough — invest in Normotim.